The OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXIâ„¢ provides complete protocol support for AXI3â„¢, AXI4â„¢, AXI4-Liteâ„¢, AXI4-Streamâ„¢, ACEâ„¢, ACE-Liteâ„¢ , AHBâ„¢ and APBâ„¢ interfaces. ... Synopsys® VC ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of ...
Moderna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to have its vaccine for respiratory syncytial ...
Moderna Inc. has landed its second product approval from the U.S. Food and Drug Administration after its COVID-19 vaccine. The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus ...
The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that ...